Prostate cancer is the most common visceral malignancy and the second leading cause of cancer deaths in US men.
There is broad evidence that fibroblast growth factor (FGF) receptors are important in prostate cancer initiation and progression, but the contribution of particular FGFs in this disease is not fully understood. The FGF family members FGF19, FGF21, and FGF23 comprise a distinct subfamily that circulate in serum and act in an endocrine manner. These endocrine FGFs require α-Klotho (KL) and/or β-Klotho (KLB), two related single-pass transmembrane proteins restricted in their tissue distribution, to act as coreceptors along with classic FGF receptors (FGFR) to mediate potent biologic activity. Here we show that FGF19 is expressed in primary and metastatic prostate cancer tissues, where it functions as an autocrine growth factor. Exogenous FGF19 promoted the growth, invasion, adhesion, and colony formation of prostate cancer cells at low ligand concentrations. FGF19 silencing in prostate cancer cells expressing autocrine FGF19 decreased invasion and proliferation in vitro and tumor growth in vivo. Consistent with these observations, KL and/or KLB were expressed in prostate cancer cells in vitro and in vivo, raising the possibility that additional endocrine FGFs may also exert biologic effects in prostate cancer. Our findings support the concept that therapies targeting FGFR signaling may have efficacy in prostate cancer and highlight FGF19 as a relevant endocrine FGF in this setting.
Written by:
Feng S, Dakhova O, Creighton CJ, Ittmann M. Are you the author?
Department of Pathology and Immunology and Michael E. DeBakey Department of Veterans Affairs Medical Center; and Dan L. Duncan Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, Texas.
Reference: Cancer Res. 2013 Apr 15;73(8):2551-62.
doi: 10.1158/0008-5472.CAN-12-4108
PubMed Abstract
PMID: 23440425
UroToday.com Investigative Urology Section
